RCORP-TA is offering live Zoom sessions on the third Wednesday of each month at 1:00pm EST/12:00 pm CST. These sessions are specifically for rural providers who are prescribing or considering prescribing medications for opioid use disorder (MOUD) and would like to network and have informal discussions with their rural peers throughout the country.
This opportunity is hosted by JBS Senior Medical Officer Dr. Melinda Campopiano and JBS Deputy Project Director Jason Harris, MS, MPA, CWMF.
This truly is a “come as you are” opportunity; it is ok to come late or leave early. The sessions will serve as an informal space for rural providers to give and receive peer feedback, and share their questions, challenges and success in relation to prescribing MOUD.
To sign up, please use the link below to confirm eligibility. Once you sign up, you will receive an invite to the series you selected; once you accept the invite, the series will be on your calendar for you to attend when able, with no expectations beyond participating when it works for you.
To learn more about our Peer to Peer opportunities, click the link below to view the current opportunities:
Buprenorphine
- The below 2021 study presents reassuring data on drug-drug interactions with the Sublocade
- Findings In this cohort study using difference-in-differences analyses of 17 428 Medicaid-enrolled adults with an opioid use disorder emergency department encounter, the buprenorphine treatment O-HQIP pathway was associated with significantly increased prescription fills for buprenorphine within 30 days of discharge.
- ASAM Literature Review Article – Clinical Considerations Buprenorphine
-
Correctional Services and Reentry
- Jail communications
- We also spoke briefly about the experience of another grantee who gets notifications when there is a new person incarcerated at their jail and is able to “reach in” to make contact with them through the jails controlled communication system. This is the system she described using: Friends and Family - Cidnet. Note, this mention does not constitute an endorsement of this product.
Fentanyl
- This is a recent, especially relevant resource from PCSS that addresses much of the uncertainty around initiating buprenorphine for people using or consistently exposed to fentanyl.
- This is the retrospective chart review quantifying precipitated withdrawal (N=13). You have to look at the supplementary data to find out this is 13 out of 931 charts which is 1.4%.
- This is Gail D’Onofrio’s prospective study of precipitated withdrawal in the ED. This study found the incidence of precipitated withdrawal to be less than 1% despite high fentanyl prevalence.
MOUD Implementation and Training
- Article from 2023 that goes over some of the challenges with provider recruitment in rural areas.
- Sample policy and procedure for MOUD delivery
- I found some policy and procedure exemplars. Beware I have not fully vetted these but upon a quick review I see no red flags. These are all several years old and would need to be tailored to your own setting/community but they can serve as a starting point.
- MAT-procedure-11.15.19.pdf (careinnovations.org)
- MAT-Workflow.pdf (jeffersonhealthcare.org)
- This one is for corrections: Buprenorphine Prescription Policy (iphca.org)
Resources: Prior Authorizations
Resources for Providers
- PCSS is a great resource for both new and seasoned providers. They also offer a free mentor program, along with the ability to join an online discussion forum and submit a clinical question.
- The other clinical resource we discussed regarding starting buprenorphine was CA Bridge which is rebranding itself as Bridge to Treatment. Their website is loaded with resources and trainings. I attached a pdf of all their protocols in one packet. You can download each protocol separately from their website if you want to be selective about what you share so you don’t overwhelm anyone.